Ocugen, Inc. (OCGN) Stock

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Ocugen, Inc. is led by CEO Shankar Musunuri, publicly traded since 2014.

Ocugen, Inc. (OCGN) stock trades at $0.74 with a market capitalization of $250.84M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.09, reflecting a net loss over the last twelve months, a negative price-to-book of -15.96, reflecting negative shareholders' equity, price-to-sales of 57.77. Over the past 52 weeks the stock has ranged between $0.73 and $2.73, and currently trades 72.9% below its 52-week high.

On profitability, Ocugen, Inc. generates a return on equity (ROE) of 566.67% (not meaningful, as shareholders' equity is negative), return on capital employed of 776.46%, an operating margin of -1575.00%, a net profit margin of -16.05%.

Official website: www.ocugen.com

Ocugen, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Ocugen, Inc. reported revenue of $0 rising to $4.0M. Compounded, revenue has grown —% a year over five years, 26.0% over three, 0.0% over the last twelve months. Net profit fell to $-68.0M.

The most recent net margin is -16.05%. On a trailing twelve-month basis to Jun '26, revenue is $5.0M and net profit $-82.0M.

Borrowings rose from $1.0M to $33.0M, cash on hand is $100.0M, cash from operations was $-57.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 11.0% over five years, and was 566.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Ocugen, Inc. (OCGN) — frequently asked questions